Events - Pharvaris N.V.

Upcoming Events

Nov 30 - Dec 1, 2026

The British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference 2026

Dec 2, 2026 10:00 AM EST

9th Annual Evercore Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Dec 4 - Dec 6, 2026

The Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) 2026 Congress

Dec 9 - Dec 10, 2026

8th Global Urticaria Forum (GUF) 2026

Past Events

Oct 1 - Oct 3, 2026

21st German Allergy Congress (DAK)

Supporting Materials

Oral Deucrictibant Immediate-release Capsule for On-demand Treatment of Hereditary Angioedema Attacks: Phase 3 RAPIDe-3 Trial Results 839.8 KB

Long-term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the CHAPTER-1 Open-label Extension Study 867.4 KB

Sep 16, 2026 8:00 AM EDT

H.C. Wainwright 28th Annual Global Investment Conference

Click for Webcast

Sep 15, 2026 7:45 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Click for Webcast

Sep 10, 2026 1:35 PM EDT

2026 Cantor Global Healthcare Conference

Click for Webcast

Sep 9, 2026 4:30 PM EDT

Wells Fargo 21st Annual Healthcare Conference

Click for Webcast

Sep 8, 2026 8:00 AM EDT

Pharvaris Reports Topline CHAPTER-3 Data

Listen to webcast

Supporting Materials

CHAPTER-3 Topline Data 804.1 KB

Sep 3 - Sep 4, 2026

Bradykinin Symposium 2026

Supporting Materials

Modelling human, rat, and humanized bradykinin B2 receptor-deucrictibant complexes in-silico 2.7 MB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial 1.1 MB

Clinical Cardiovascular Safety Evaluation of Oral Deucrictibant 1 MB

Evaluating Safety Margins of the Use of Deucrictibant Immediate-Release Capsule in Combination With Deucrictibant Extended-Release Tablet 168.8 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 448.7 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema 186.9 KB

End Of Progression of Attack Manifestations With Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks in the Phase 3 RAPIDe-3 Trial 220.4 KB

End-of-Progression Using Patient Global Impression of Change Validation in RAPIDe-3 214.5 KB

LC-MS particle-based plasma proteomics in bradykinin-mediated angioedema 1.2 MB

The NHP Bradykinin Challenge Model Predicts Human Deucrictibant Efficacious Doses 1.2 MB

Aug 6 - Aug 9, 2026

Argentine Association of Allergy and Clinical Immunology (AAAeIC) Annual Congress 2026

Supporting Materials

Oral deucrictibant immediate-release capsule for the on-demand treatment of hereditary angioedema attacks: Results of the RAPIDe-3 Phase 3 trial 254.5 KB

Cessation of hereditary angioedema attack progression in the RAPIDe-3 Phase 3 trial of oral deucrictibant immediate-release capsules for on-demand treatment 401.8 KB

Jun 26, 2026 10:00 AM EDT

2026 Annual General Meeting of Shareholders

Supporting Materials

Annual Report 2025 4 MB

Convening Notice and Agenda 259.8 KB

Voting Proxy 198.5 KB

Executed Minutes 779.7 KB

Jun 12 - Jun 15, 2026

European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2026

Supporting Materials

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial 1.2 MB

Clinical Cardiovascular Safety Assessment of Oral Deucrictibant 712.7 KB

A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema 394.9 KB

Evaluations of Safety Margins and Response to Deucrictibant Extended-Release (XR) Tablet in Combination with Deucrictibant Immediate-Release (IR) Capsule 174.5 KB

Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial 262.8 KB

RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 254.2 KB

Results of the Phase 2 CHAPTER-1 Open-Label Extension Study on the Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema 202.8 KB

CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema 200.7 KB

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
…
Next page
Last page